Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...

For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Tuberculosis (TB) is a bacterial infection that usually affects the lungs but can spread to other parts of the body, including the skin. Once it reaches the skin, TB can cause a variety of lesions ...

PUPPP stands for pruritic urticarial papules and plaques of pregnancy. Also known as polymorphic eruption of pregnancy (PEP), it is one of the most common types of rash you can get during pregnancy.

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe.

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study Topline results from ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB’s Bimzelx achieved complete skin clearance. After five years of continued ...